Trials / Completed
CompletedNCT04971928
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
A Phase 1, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics of GSK3228836 in Adults With Hepatic Impairment and Healthy Matched Control Participants (B-Assured)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, open-label, parallel-group study to evaluate the pharmacokinetics of GSK3228836 in participants with Child-Pugh B (CP-B) cirrhosis (moderate hepatic impairment), Child-Pugh A (CP-A) cirrhosis (mild hepatic impairment) and participants with normal hepatic function as healthy control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK3228836 | GSK3228836 will be administered |
Timeline
- Start date
- 2021-09-07
- Primary completion
- 2022-05-12
- Completion
- 2022-05-12
- First posted
- 2021-07-22
- Last updated
- 2022-09-27
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04971928. Inclusion in this directory is not an endorsement.